This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
by Ritujay Ghosh
Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
Should Value Investors Buy Encompass Health (EHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Encompass Health (EHC) Stock Down Despite Q1 Earnings Beat
by Zacks Equity Research
Encompass Health (EHC) increases its guidance for net operating revenues, which is in the range of $5.25-$5.325 million for 2024.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Why Encompass Health (EHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.